# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

k091333 B. Purpose for Submission: New device C. Measurand: Low Density Lipoprotein Cholesterol (LDL-C) D. Type of Test: LDL-C reagent cartridges, used with the S40 Clinical Analyzer, intended for the quantitative determination of LDL-C based on an enzymatic photometric assay. E. Applicant: Alfa Wassermann, Inc. F. Proprietary and Established Names: S-Test LDL Cholesterol (LDL) G. Regulatory Information:

1. Regulation section: 21 CFR 862.1475 – Lipoprotein Test System

2. Classification: Class I, meets the limitations to the exemption (21 CFR 862.9(c)(4))

3. Product code: MRR – System, Test, Low Density Lipoprotein

4. Panel:

# Clinical Chemistry

# H. Intended Use:

1. Intended use(s): Refer to indications for use below.

2. Indication(s) for use:

The S-Test Low Density Lipoprotein Cholesterol Reagent is intended for the quantitative determination of LDL concentration in serum or heparin plasma using the S40 Clinical Analyzer. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, various liver and renal diseases. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

3. Special conditions for use statement(s): For prescription use only. For in vitro diagnostic use only.

4. Special instrument requirements: S40 Clinical Analyzer

# I. Device Description:

The S-Test Low Density Lipoprotein (LDL) cholesterol reagent cartridge, used with the S40 Clinical Analyzer, is a single-use bi-reagent plastic cartridge consisting of liquid stable reagents and a reaction cavity, together with a bar code label. The bar code contains all chemistry parameters, calibration factors, and other productionrelated information. The bi-reagent cartridge contains the following materials: 4- Aminoantipyrine $( 0 . 0 1 \% )$ , cholesterol esterase $( < 2 . 5 \mathrm { U } / \mathrm { m L } )$ , cholesterol oxidase (1.2 $\mathrm { I U / m L }$ ), peroxidase $( < 1 . 3 \mathrm { p p g } \mathrm { U / m L } )$ ), surfactant 1 and 2, DSBmT $( 0 . 0 4 \% )$ , and Good’s Buffer $\mathrm { ( p H } 6 . 3 )$ .

# J. Substantial Equivalence Information:

1. Predicate device name(s): ACE Low Density Lipoprotein Cholesterol Reagent

2. Predicate 510(k) number(s):

# k991733

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Comparison Table</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device (k091333)</td><td colspan="1" rowspan="1">Predicate (k991733)</td></tr><tr><td colspan="1" rowspan="1">Indications for Use</td><td colspan="1" rowspan="1">The S-Test Low DensityLipoprotein CholesterolReagent is intended for thequantitative determination ofLDL concentration in serumor heparin plasma using theS40 Clinical Analyzer.Lipoprotein measurementsare used in the diagnosis andtreatment of lipid disorders(such as diabetes mellitus),atherosclerosis, various liverand renal diseases, and forthe assessment of the risk ofdeveloping cardiovasculardisease. This test is intendedfor use in clinicallaboratories or physicianoffice laboratories. For invitro diagnostic use only.</td><td colspan="1" rowspan="1">ACE LDL-C Reagent isintended for the quantitativedetermination of low densitylipoprotein cholesterol(LDL-C) in serum using theACE and NExCT clinicalchemistry systems. For invitro diagnostic use only.</td></tr><tr><td colspan="1" rowspan="1">Measurand</td><td colspan="1" rowspan="1">LDL Cholesterol</td><td colspan="1" rowspan="1">LDL Cholesterol</td></tr><tr><td colspan="1" rowspan="1">Dimensions</td><td colspan="1" rowspan="1">Two cartridge reservoirs todeliver 210 µL and then 70μL of reagent to reactioncuvette</td><td colspan="1" rowspan="1">Bottles with total volumes of10 and 30 mL containingreagents.</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">S40 Clinical Analyzer</td><td colspan="1" rowspan="1">ACE and NExCT ClinicalChemistry Systems</td></tr><tr><td colspan="1" rowspan="1">Reaction Type</td><td colspan="1" rowspan="1">Endpoint</td><td colspan="1" rowspan="1">Endpoint</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum or heparin plasma</td><td colspan="1" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">Sample Volume</td><td colspan="1" rowspan="1">5 μL</td><td colspan="1" rowspan="1">3 μL</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Each lot is calibrated by themanufacturer prior toshipment using materialtraceable to β-QuantificationReference Method (CDC).The 2-D barcode printed oneach cartridge provides theanalyzer with lot-specificcalibration data.</td><td colspan="1" rowspan="1">Calibrated by referencing thechange in absorbance of theunknown samples to thechange in absorbance of thestandard.</td></tr><tr><td colspan="1" rowspan="1">Use of Controls</td><td colspan="1" rowspan="1">Two levels of control per day</td><td colspan="1" rowspan="1">Two levels of control per day</td></tr><tr><td colspan="1" rowspan="1">Linearity Range</td><td colspan="1" rowspan="1">11 to 396 mg/dL</td><td colspan="1" rowspan="1">3 to 800 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Detection Limit</td><td colspan="1" rowspan="1">1 mg/dL</td><td colspan="1" rowspan="1">3 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Reagent Stability</td><td colspan="1" rowspan="1">Low Density LipoproteinCholesterol cartridges arestable until the expirationdate on the box labels whenstored at 2-8°C</td><td colspan="1" rowspan="1">Unopened LDL reagent isstable until the expirationdate shown on the box andbottle labels when stored at2-8°C</td></tr><tr><td colspan="1" rowspan="1">Testing Environment</td><td colspan="1" rowspan="1">Clinical laboratories orphysician office laboratories</td><td colspan="1" rowspan="1">Clinical laboratories orphysician office laboratories</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

1. CLSI EP6-A – Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach (2003)   
2. CLSI EP7-A2 – Interference Testing in Clinical Chemistry (2005)   
3. CLSI EP5-A2 – Evaluation of Precision Performance of Quantitative Measurement Methods (2004)   
4. CLSI EP10-A3 – Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures (2006)   
5. CLSI EP9-A2 – Method Comparison and Bias Estimation Using Patient Samples (2002)   
6. CLSI EP17-A – Protocols for Determination of Limits of Detection and Limits of Quantitation (2004)

# L. Test Principle:

The single-use LDL reagent plastic container is composed of a bi-reagent cartridge holding two stable reagents, a reaction cavity, and a bar code label. The test is based on a photometric measurement of the amount of LDL present after other non-LDL cholesterol is solubilized by a detergent and then consumed by cholesterol esterase and cholesterol oxidase in a non-color forming reaction. LDL is then solubilized by a second detergent in the presence of a chromogenic peroxidase substrate to form a purple-red color. The amount of color formed, determined by measuring the increase in absorbance bichromatically at $5 4 6 / 6 6 0 \ \mathrm { n m }$ on the S40 Clinical Analyzer, is directly proportional to the LDL cholesterol concentration.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility:

In-house precision studies were conducted as follows: three serum samples (with normal, intermediate, and elevated levels) were tested for LDL on one S40 Clinical Analyzer two times per run, two runs per day, for a total of 22 days. The mean, standard deviation, and $\%$ coefficients of variation (CV) were calculated for each sample.

<table><tr><td rowspan=1 colspan=1>Sample 1Mean = 36 mg/dL LDL</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation,mg/dL</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>2.5%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 2Mean = 186 mg/dL LDL</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation,mg/dL</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>2.4%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 3Mean = 337 mg/dL LDL</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation,mg/dL</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>7.3</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>2.2%</td></tr></table>

Precision Studies were also conducted at three Physician Office Laboratories (POL). Three serum samples (with normal, intermediate, and elevated levels) were tested for LDL on three S40Clinical Analyzers (one at each lab) three times per run, one run per day, for a total of 5 days. The mean, standard deviation, and $\%$ coefficients of variation (CV) were calculated for each sample.

<table><tr><td colspan="3" rowspan="1"></td><td colspan="2" rowspan="1">% CV or SD (mg/dL)</td></tr><tr><td colspan="1" rowspan="1">Lab</td><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Mean</td><td colspan="1" rowspan="1">Within-Run</td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="2">POL 1</td><td colspan="1" rowspan="2">1</td><td colspan="1" rowspan="2">41</td><td colspan="1" rowspan="1">1.2 SD</td><td colspan="1" rowspan="1">1.2 SD</td></tr><tr><td colspan="1" rowspan="1">2.8%</td><td colspan="1" rowspan="1">2.8%</td></tr><tr><td colspan="1" rowspan="2">POL 2</td><td colspan="1" rowspan="2">1</td><td colspan="1" rowspan="2">41</td><td colspan="1" rowspan="1">0.5 SD</td><td colspan="1" rowspan="1">1.0 SD</td></tr><tr><td colspan="1" rowspan="1">1.1%</td><td colspan="1" rowspan="1">2.4%</td></tr><tr><td colspan="1" rowspan="2">POL 3</td><td colspan="1" rowspan="2">1</td><td colspan="1" rowspan="2">38</td><td colspan="1" rowspan="1">0.4 SD</td><td colspan="1" rowspan="1">0.5 SD</td></tr><tr><td colspan="1" rowspan="1">1.0%</td><td colspan="1" rowspan="1">1.4%</td></tr><tr><td colspan="1" rowspan="2">POL 1</td><td colspan="1" rowspan="2">2</td><td colspan="1" rowspan="2">189</td><td colspan="1" rowspan="1">1.6 SD</td><td colspan="1" rowspan="1">2.4 SD</td></tr><tr><td colspan="1" rowspan="1">0.9%</td><td colspan="1" rowspan="1">1.3%</td></tr><tr><td colspan="1" rowspan="2">POL 2</td><td colspan="1" rowspan="2">2</td><td colspan="1" rowspan="2">186</td><td colspan="1" rowspan="1">2.7 SD</td><td colspan="1" rowspan="1">2.7 SD</td></tr><tr><td colspan="1" rowspan="1">1.5%</td><td colspan="1" rowspan="1">1.5%</td></tr><tr><td colspan="1" rowspan="2">POL 3</td><td colspan="1" rowspan="2">2</td><td colspan="1" rowspan="2">180</td><td colspan="1" rowspan="1">1.4 SD</td><td colspan="1" rowspan="1">2.1 SD</td></tr><tr><td colspan="1" rowspan="1">0.8%</td><td colspan="1" rowspan="1">1.2%</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="1" rowspan="2">POL 1</td><td colspan="1" rowspan="2">3</td><td colspan="1" rowspan="2">358</td><td colspan="1" rowspan="1">5.6 SD</td><td colspan="1" rowspan="1">7.1 SD</td></tr><tr><td colspan="1" rowspan="1">1.6%</td><td colspan="1" rowspan="1">2.0%</td></tr><tr><td colspan="1" rowspan="2">POL 2</td><td colspan="1" rowspan="2">3</td><td colspan="1" rowspan="2">352</td><td colspan="1" rowspan="1">6.0 SD</td><td colspan="1" rowspan="1">6.5 SD</td></tr><tr><td colspan="1" rowspan="1">1.7%</td><td colspan="1" rowspan="1">1.8%</td></tr><tr><td colspan="1" rowspan="2">POL 3</td><td colspan="1" rowspan="2">3</td><td colspan="1" rowspan="2">339</td><td colspan="1" rowspan="1">5.5 SD</td><td colspan="1" rowspan="1">6.7 SD</td></tr><tr><td colspan="1" rowspan="1">1.6%</td><td colspan="1" rowspan="1">2.0%</td></tr></table>

# b. Linearity/assay reportable range:

Commercial linearity standards at 11 different levels with values ranging from 11 to $3 9 6 \mathrm { m g / d L }$ were used to determine linearity across the assay range. The mean value of each set of quadruplicate determinations was determined. Percent recoveries ranged from $90 \mathrm { - } 1 0 2 \%$ . The linear regression equation obtained for the study was $\mathrm { y } = 1 . 0 1 1 \mathrm { x } - 4 . 2 5$ , $\Gamma ^ { 2 } = 0 . 9 9 9 \overline { { 6 } }$ .

The LDL assay reportable range using the S-Test LDL Cholesterol reagent cartridge on the S40 Clinical Analyzer is 11 to $3 9 6 \mathrm { m g / d L }$ . If a sample is less than $1 1 \mathrm { m g / d L }$ , the result is flagged by the analyzer $\mathrm { { 1 s < 1 1 m g / d L } }$ -Range. If a sample result exceeds $3 9 6 ~ \mathrm { m g / d L }$ , the result is flagged by the analyzer as $>$ 396 mg/dL-Range.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Each lot of S-Test LDL Cholesterol reagent cartridges is factory calibrated and traceable to the $\beta$ -Quantification Reference Method. The 2-D barcode printed on each cartridge provides the S-40 Clinical Analyzer with lot-specific calibration data. This method has not been tested or certified by the Cholesterol Reference Method Laboratory Network.

Stability of reagent cartridges was determined at $2 { \cdot } 1 0 ^ { \circ } \mathrm { C }$ using real-time studies. Accuracy and precision data substantiate the stability claim of 12 months when stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ .

d. Detection limit:

The limit of detection was determined by assaying five low samples (serum samples) and five true blanks (human serum albumin in saline). Testing was carried out over three days on two S40 Clinical Analyzers. Both, the low samples and true blanks, were run every day for a total of replicates $\scriptstyle \mathrm { n = 6 0 }$ . The limit of detection was determined to be $1 \mathrm { m g / d L }$ . The assay reportable range is 11 to $3 9 6 \mathrm { m g / d L }$ on the S40 Clinical Analyzer. If a sample is less than $1 1 \mathrm { m g / d L }$ , the result is flagged by the analyzer a $\mathrm { s } < 1 1 \mathrm { m g } / \mathrm { d }$ L-Range.

# e. Analytical specificity:

Interference studies to determine the effect of Ascorbic Acid, Unconjugated Bilirubin, Hemolysis, and Triglycerides were performed. Serum pools containing normal and abnormal LDL cholesterol were spiked with various concentrations of ascorbic acid, unconjugated bilirubin, and hemoglobin as described in table below.

<table><tr><td rowspan=1 colspan=1>Interference</td><td rowspan=1 colspan=1>Normal LDL-C(mg/L)</td><td rowspan=1 colspan=1>Abnormal LDL-C(mg/L)</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid(serum: 1.6 - 50 mg/dL)</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>140</td></tr><tr><td rowspan=1 colspan=1>Unconjugated Bilirubin(serum: 1.6 - 50 mg/dL)</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>142</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin(serum: 31 - 1000 mg/dL).</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>142</td></tr></table>

Triglycerides $( 3 0 0 - 1 1 7 0 \mathrm { m g / d L } )$ were evaluated using four lipemic serum samples. All samples were tested in triplicate on the S40 Clinical Analyzer. Results from interference studies are described in the device labeling as follows. Ascorbic Acid and Bilirubin showed no significant interference at the tested conditions. No significant interference from hemolysis was detected for the normal sample. Hemoglobin concentrations greater than 500 $\mathrm { m g / d L }$ may cause interference. Negative interference occurred at $1 0 0 0 \mathrm { m g / d L }$ on the abnormal sample. Triglycerides showed no significant interference below $5 8 9 \mathrm { m g / d L }$ . Triglyceride concentrations greater than $5 8 9 \mathrm { m g / d L }$ may cause interference. Negative interference occurred at $1 1 7 0 \mathrm { m g / d L }$ triglycerides.

f. Assay cut-off: Not applicable

2. Comparison studies:

# a. Method comparison with predicate device:

A series of 110 serum specimens with LDL cholesterol values ranging from 11 to $3 8 8 \mathrm { m g / d L }$ were assayed on the S40 Clinical Analyzer using the S-Test LDL Reagent and the ACE Clinical Chemistry System using the ACE LDL-C Reagent as the reference method. Least-squares regression analysis yielded the following results:

<table><tr><td rowspan=1 colspan=1>Regression Equation</td><td rowspan=1 colspan=1>y = 0.965x + 0.85</td></tr><tr><td rowspan=1 colspan=1>Correlation Coefficient</td><td rowspan=1 colspan=1>0.9958</td></tr><tr><td rowspan=1 colspan=1>Std. Error Est.</td><td rowspan=1 colspan=1>6.57</td></tr><tr><td rowspan=1 colspan=1>Confidence Interval Slope</td><td rowspan=1 colspan=1>0.948 to 0.982</td></tr><tr><td rowspan=1 colspan=1>Confidence Interval Intercept</td><td rowspan=1 colspan=1>-1.73 to 3.42</td></tr></table>

# Point of Care in Physician’s Office Laboratories

Performance for the S-Test LDL cholesterol reagent was evaluated at three Physician Office Laboratories (POL). Operators assayed $> 4 0$ serum samples on the S40 Clinical Analyzer and the ACE Clinical Chemistry System. The following linear regression data was obtained:

<table><tr><td rowspan=1 colspan=1>POL</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>49</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>12-348</td><td rowspan=1 colspan=1>16-348</td><td rowspan=1 colspan=1>13-322</td></tr><tr><td rowspan=1 colspan=1>Regression Equation</td><td rowspan=1 colspan=1>y = 0.939x + 7.95</td><td rowspan=1 colspan=1>y = 0.922x +8.93</td><td rowspan=1 colspan=1>y = 0.936x -0.92</td></tr><tr><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>0.9945</td><td rowspan=1 colspan=1>0.9953</td><td rowspan=1 colspan=1>0.9968</td></tr><tr><td rowspan=1 colspan=1>Standard Error</td><td rowspan=1 colspan=1>7.77</td><td rowspan=1 colspan=1>8.03</td><td rowspan=1 colspan=1>5.95</td></tr><tr><td rowspan=1 colspan=1>Confidence IntervalSlope</td><td rowspan=1 colspan=1>0.910 to 0.967</td><td rowspan=1 colspan=1>0.895 to 0.949</td><td rowspan=1 colspan=1>0.914 to 0.959</td></tr><tr><td rowspan=1 colspan=1>Confidence IntervalIntercept</td><td rowspan=1 colspan=1>3.58 to 12.32</td><td rowspan=1 colspan=1>4.28 to 13.58</td><td rowspan=1 colspan=1>-4.56 to 2.72</td></tr></table>

# b. Matrix comparison:

A study was performed by assaying LDL cholesterol determinations on 34 paired samples drawn from the same patients in serum and lithium heparin plasma tubes at a clinical laboratory. All specimens were assayed on the S40 Clinical Analyzer using S-Test LDL cartridges. The serum results ranged

from 13 to $3 5 0 \mathrm { m g / d L }$ . Least-square regression analysis yielded the following results (serum $\mathbf { X }$ -axis; plasma y-axis):

<table><tr><td rowspan=1 colspan=1>Regression Equation</td><td rowspan=1 colspan=1>y = 0.998x - 0.81</td></tr><tr><td rowspan=1 colspan=1>Correlation Coefficient</td><td rowspan=1 colspan=1>0.9990</td></tr><tr><td rowspan=1 colspan=1>Std. Error Est.</td><td rowspan=1 colspan=1>3.61</td></tr><tr><td rowspan=1 colspan=1>Confidence Interval Slope</td><td rowspan=1 colspan=1>0.982 to 1.014</td></tr><tr><td rowspan=1 colspan=1>Confidence Interval Intercept</td><td rowspan=1 colspan=1>-3.10 to 1.48</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not applicable   
b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

The S-Test LDL cholesterol reagent uses the LDL reference range recommendations on lipid testing and management published in the “Third Report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults (Adult Treatment Panel III); Final Report.

<table><tr><td rowspan=1 colspan=2>LDL Cholesterol (mg/dL)</td></tr><tr><td rowspan=1 colspan=1>&lt; 100</td><td rowspan=1 colspan=1>Optimal</td></tr><tr><td rowspan=1 colspan=1>100-129</td><td rowspan=1 colspan=1>Near optimal/above optimal</td></tr><tr><td rowspan=1 colspan=1>130-159</td><td rowspan=1 colspan=1>Borderline High</td></tr><tr><td rowspan=1 colspan=1>160-189</td><td rowspan=1 colspan=1>High</td></tr><tr><td rowspan=1 colspan=1>≥ 190</td><td rowspan=1 colspan=1>Very High</td></tr></table>

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.